NCT03017963View on ClinicalTrials.gov

Safety and Tolerability of Sodium Thiosulfate in Patients With an ACS Undergoing CAG Via Trans-radial Approach.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 6, 2017

Primary Completion Date

March 23, 2018

Study Completion Date

March 23, 2018

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Sodium Thiosulfate Pentahydrate

Sodium Thiosulfate Pentahydrate is administered intravenously in 250 centiliters infusion fluid in two doses: first dose with an infusion rate of 16.66 milliliter (ml) per minute (min), second dose with 8.33 ml / min

Trial Locations (1)

9700RB

University Medical Centre Groningen, Groningen

All Listed Sponsors
lead

University Medical Center Groningen

OTHER

NCT03017963 - Safety and Tolerability of Sodium Thiosulfate in Patients With an ACS Undergoing CAG Via Trans-radial Approach. | Biotech Hunter | Biotech Hunter